JAN 20, 2019 06:31 PM PST

Combination Therapeutic Effective for Leishmaniasis and HIV Patients

WRITTEN BY: Nouran Amin

In a study published in PLOS Neglected Diseases, a special combination therapy has been proven for efficacy in cases of coinfection with Visceral leishmaniasis (VL) and human immunodeficiency virus (HIV). As of now, the World Health Organization (WHO) recommends AmBisome monotherapy for treatment, however, the study proposed a combination therapy of AmBisome and another drug called ‘miltefosine’ to be more effective.

Learn more about Visceral Leishmaniasis (VL) and HIV Coinfection from a patient perspective:

Research has confirmed that 30 mg/kg of AmBisome is effective in 43-70% of patients with an HIV co-infection. However, AmBisome brings the proneness of toxicity and an increased risk of death. HIV increases the incidence of VL by altering it symptoms and worsening the illness along with treatment outcomes and rates of relapse.

Séverine Blesson and team, who are working on the Drugs for Neglected Diseases Initiative in Switzerland, began a compassionate use of clinical studies in a treatment facility in Northwest Ethiopia consisting of combining AmBisome and miltefosine. Measurements of efficacy were taken according to parasite clearance at 29 days and 58 days. Results showed that after 29 days measurements for efficacy was 50% for AmBisome and 67% for the combination therapy. At 58 days, 55% efficacy was measured for the monotherapy and 88% for the combination treatment.

HIV infection remains a challenge for the control of visceral leishmaniasis (VL) control.

Credit: PLOS Collections Blog - Biology & Life Sciences

The study showed no safety concerns about the combination therapy. "The results of this randomized trial strongly support a change in the treatment recommendations for HIV-VL co-infected patients," noted the researchers—however, they do caution, "these results, even if encouraging, cannot be extrapolated to other settings without reservation."

Source: Science Daily

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 31, 2018
Drug Discovery
OCT 31, 2018
Cytostatic Drug Proved Potent For Cancer
A study published in journal Angewandte Chemie, describes how a cytostatic drug, consisting of therapeutically active molecules that is linked to specific ...
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Super-Drug for Pediatric Leukemia?
In a final study published in Genes & Development, researchers at Northwestern University School of Medicine concluded their discoveries on two success...
JAN 12, 2019
Drug Discovery
JAN 12, 2019
The Harms of Prescription Sleeping Pills
In a study published by Frontiers in Behavioral Neuroscience, one of the main class of prescription sleeping pills was found to reduce the ability to wake...
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Drug Blocks Toxic-Protein Production in ALS
Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in ...
FEB 04, 2019
Microbiology
FEB 04, 2019
Potential New Antibiotic is Made by an Insect-linked Microbe
Like many other organisms, bacteria have to compete for resources and have developed a wide array of strategies to use, including antibiotics....
FEB 08, 2019
Drug Discovery
FEB 08, 2019
Apsirin Use Prevents Colorectal Cancer
In a study published in the American Journal of Medicine, the U.S. Preventive Services Task Force (USPSTF) concluded that aspirin use decreases the risk of...
Loading Comments...